Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
August 30, 2022 15:35 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Comments on Recent Trading Activity
August 18, 2022 15:34 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
June 27, 2022 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
May 12, 2022 06:50 ET
|
Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds...
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
May 02, 2022 06:50 ET
|
Bright Minds Biosciences
-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry,...
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
April 19, 2022 06:50 ET
|
Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) --...
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
March 14, 2022 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 08, 2022 07:30 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
January 04, 2022 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
December 06, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...